CTSO - CytoSorbents to Report First Quarter 2024 Operating and Financial Results | Benzinga
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024.
CytoSorbents' management will host a live conference call and presentation webcast and a question and answer session starting at 4:30PM EDT the same day.
Webcast Details:
Date: Thursday, May 9th, 2024
Time: 4:30 PM EDT
Live webcast link: https://edge.media-server.com/mmc/p/yv8wd3bs
Conference ID: 5517203
Participant Dial-In:
Participant Dial-in toll-free: (888) 596-4144
Passcode: 5517203
It is recommended that participants dial in approximately 10 minutes prior to the start of the call.
An archived recording of the conference call will be available under the Investor Relations section of the Company's website at https://ir.cytosorbents.com/
About CytoSorbents Corporation (NASDAQ:CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and in cardiac surgery through blood purification. Its lead product, CytoSorb®, is approved in the European Union and distributed in 75 countries worldwide. It is an extracorporeal cytokine adsorber that reduces "cytokine storm" or "cytokine release syndrome" in common critical illnesses that can lead to massive inflammation, organ failure and patient death. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments. CytoSorb is also used during and after cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, including severe bleeding and multiple organ failure. At the end of 2023, more than 228,000 CytoSorb devices had been ...